21.03.2017
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG expands patent protection for Aurase(R) enzyme for the treatment of chronic wounds
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Patent
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG
expands patent protection for Aurase(R) enzyme for the treatment of chronic
wounds
21.03.2017 / 08:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
BRAIN AG expands patent protection for Aurase(R) enzyme for the treatment of
chronic wounds
* Patent protection in 20 countries of the most important entry markets
* Possible fields of application address, among others, the growing
markets for the treatment of chronic wounds
* BRAIN engaged in discussions regarding different partnership options in
the BioIndustrial business segment
Zwingenberg, March 21, 2017: B.R.A.I.N. Biotechnology Research and
Information Network AG ("BRAIN AG"; ISIN DE0005203947 / WKN 520394) has
obtained far-reaching patent protection for a newly developed enzyme with
the product name Aurase(R). For a total of 20 countries in Europe, Asia,
North America, Oceania and Africa, this laid the foundation for the later
marketing of applications based on Aurase(R) in the fields of skin and scar
treatment as well as the strongly growing market for the care of chronic
wounds. The development of Aurase(R) is part of the portfolio of BRAIN's
BioIndustrial business segment. Currently, BRAIN is evaluating concrete
application possibilities for Aurase(R) and is engaged in discussions with
industrial partners regarding different marketing strategies.
Aurase(R) offers the possibility to improve the efficient and conservative
treatment of chronic wounds in hospitals and surgeries as well as in
home-based health care. Substantial tests have shown that Aurase(R) is
efficient and well-tolerated. In the meantime, development activities in
BRAIN's laboratories are well advanced and they are targeted at achieving a
clearly enhanced production method for Aurase(R).
"With Aurase(R) we are further expanding our BioIndustrial business segment,
which is dedicated to the development and marketing of our products and
product components via own sales channels or in cooperation with partner
companies," according to Dr Jürgen Eck, CEO of BRAIN AG. "The comprehensive
protection of our inventions by patent law here is an important
prerequisite."
There is an increasing number of patients with chronic wounds in Germany,
Europe and other regions of the world. Experts believe that the current
number is about three to four million people in Germany, who suffer from it,
with an increasing tendency. Mostly elderly people are affected. Therefore
the demographic change has an impact on the number of diseases. Another
factor are diet-related diseases such as excess weight, diabetes or
malnutrition.
The annual sales volume of the markets potentially addressed by BRAIN for
wound treatment is estimated by experts to reach more than EUR 100 million
in Europe alone. BRAIN intends to participate with Aurase(R)-based products
in this.
A more detailed version of this press release can be found at
https://www.brain-biotech.de/en/press.
About BRAIN
BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars -"BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive -collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active product
components. Further information is available at www.brain-biotech.de/en.
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: [email protected]
www.brain-biotech.de
Disclaimer
This press release contains forward- looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. There are numerous factors which
could influence the future performance by and future developments at BRAIN
AG and the BRAIN Group. Such factors include, but are not limited to,
changes in the general economic and competitive environment, risks
associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, and other factors. BRAIN AG does
not undertake any obligation to update or revise any forward-looking
statements.
---------------------------------------------------------------------------
21.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
555943 21.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN